Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.

Abstract:

:Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily contribute to the elimination of drugs from almost all therapeutic classes. Awareness of the importance of glucuronidation as a drug clearance mechanism along with increased knowledge of the enzymology of drug and chemical metabolism has stimulated interest in the development and application of approaches for the characterisation of human drug glucuronidation in vitro, in particular reaction phenotyping (the fractional contribution of the individual UGT enzymes responsible for the glucuronidation of a given drug), assessment of metabolic stability, and UGT enzyme inhibition by drugs and other xenobiotics. In turn, this has permitted the implementation of in vitro - in vivo extrapolation approaches for the prediction of drug metabolic clearance, intestinal availability, and drug-drug interaction liability, all of which are of considerable importance in pre-clinical drug development. Indeed, regulatory agencies (FDA and EMA) require UGT reaction phenotyping for new chemical entities if glucuronidation accounts for ≥25% of total metabolism. In vitro studies are most commonly performed with recombinant UGT enzymes and human liver microsomes (HLM) as the enzyme sources. Despite the widespread use of in vitro approaches for the characterisation of drug and chemical glucuronidation by HLM and recombinant enzymes, evidence-based guidelines relating to experimental approaches are lacking. Here we present evidence-based strategies for the characterisation of drug and chemical glucuronidation in vitro, and for UGT reaction phenotyping. We anticipate that the strategies will inform practice, encourage development of standardised experimental procedures where feasible, and guide ongoing research in the field.

journal_name

Pharmacol Ther

authors

Miners JO,Rowland A,Novak JJ,Lapham K,Goosen TC

doi

10.1016/j.pharmthera.2020.107689

subject

Has Abstract

pub_date

2021-02-01 00:00:00

pages

107689

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(20)30219-9

journal_volume

218

pub_type

杂志文章,评审
  • Modulation of the tumor vasculature and oxygenation to improve therapy.

    abstract::The tumor microenvironment is increasingly recognized as a major factor influencing the success of therapeutic treatments and has become a key focus for cancer research. The progressive growth of a tumor results in an inability of normal tissue blood vessels to oxygenate and provide sufficient nutritional support to t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.06.006

    authors: Siemann DW,Horsman MR

    更新日期:2015-09-01 00:00:00

  • Peroxisome proliferator-activated receptors and inflammation.

    abstract::Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptors family. PPARs are a family of 3 ligand-activated transcription factors: PPARalpha (NR1C1), PPARbeta/delta (NUC1; NR1C2), and PPARgamma (NR1C3). PPARalpha, -beta/delta, and -gamma are encoded by different genes but show sub...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.08.007

    authors: Moraes LA,Piqueras L,Bishop-Bailey D

    更新日期:2006-06-01 00:00:00

  • Mechanisms of monooxygenase induction and inhibition.

    abstract::The mechanisms of monooxygenase induction and inhibition have been discussed from the standpoint of historic development, from the current concepts about the molecular mechanism of enzyme induction, and from the various possibilities by which inhibitors can interact with the complex cytochrome P-450 monooxygenase syst...

    journal_title:Pharmacology & therapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1016/0163-7258(87)90020-9

    authors: Netter KJ

    更新日期:1987-01-01 00:00:00

  • Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

    abstract::Cardiovascular diseases cause more mortality and morbidity worldwide than any other diseases. Although many intracellular signaling pathways influence cardiac physiology and pathology, the mitogen-activated protein kinase (MAPK) family has garnered significant attention because of its vast implications in signaling an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.05.013

    authors: Javadov S,Jang S,Agostini B

    更新日期:2014-11-01 00:00:00

  • Immunotherapy in sepsis - brake or accelerate?

    abstract::Sepsis, a life threating syndrome characterized by organ failure after infection, is the most common cause of death in hospitalized patients. The treatment of sepsis is generally supportive in nature, involving the administration of intravenous fluids, vasoactive substances and oxygen plus antibiotics to eliminate the...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107476

    authors: Steinhagen F,Schmidt SV,Schewe JC,Peukert K,Klinman DM,Bode C

    更新日期:2020-04-01 00:00:00

  • The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man.

    abstract::The cardiovascular system is highly organised in time; blood pressure (BP), heart rate (HR), peripheral resistance, pressure and the release/activity of vasodilating hormones all display pronounced circadian variations. Pathophysiological events within the cardiovascular system are also not random, as shown for instan...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.11.008

    authors: Lemmer B

    更新日期:2006-09-01 00:00:00

  • Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment.

    abstract::Despite the advances in tumor identification and treatment, cancer remains the primary driver of death around the world. Also, regular treatments for the disease are incapable of targeting particular cancer types at different stages since they are not specifically focused on harmful cells since they influence both sol...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.10.010

    authors: Leite ML,da Cunha NB,Costa FF

    更新日期:2018-03-01 00:00:00

  • Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.

    abstract:UNLABELLED:Preclinical animal models are useful tools to better understand tumor initiation and progression and to predict the activity of an anticancer agent in the clinic. Ideally, these models should recapitulate the biological characteristics of the tumor and of the related tumor microenvironment (e.g. vasculature,...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.01.001

    authors: Wartha K,Herting F,Hasmann M

    更新日期:2014-06-01 00:00:00

  • Macrophage-derived angiogenesis factors.

    abstract::A majority of angiogenic factors has been shown to be produced by macrophages. This review will give a concise description of their biochemical nature, their isolation from macrophages and their angiogenic activity. Among the factors with mitogenic effects on endothelial cells are basic fibroblast growth factor (bFGF)...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90077-y

    authors: Sunderkötter C,Goebeler M,Schulze-Osthoff K,Bhardwaj R,Sorg C

    更新日期:1991-01-01 00:00:00

  • GABAB receptors as drug targets to treat gastroesophageal reflux disease.

    abstract::For many years, acid-suppressive therapy has been at the forefront of treating gastroesophageal reflux disease (GERD), yet despite the advent of the proton pump inhibitors (PPIs) some patients continue to experience persistent GERD symptoms. Therapeutic (non-surgical) options for such patients are currently limited. T...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.02.008

    authors: Lehmann A

    更新日期:2009-06-01 00:00:00

  • Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2.

    abstract::Thioredoxin 1 (Trx 1) is a 12-kDa protein with redox-active dithiol in the active site -Cys-Gly-Pro-Cys- that is ubiquitously present in the human body. Trx 1 is a defensive protein induced by various stresses and has anti-oxidative, anti-apoptotic and anti-inflammatory effects. The anti-oxidative effect of Trx 1 is m...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.04.004

    authors: Watanabe R,Nakamura H,Masutani H,Yodoi J

    更新日期:2010-09-01 00:00:00

  • The role of the leukemia inhibitory factor receptor in neuroprotective signaling.

    abstract::Several neurotropic cytokines relay their signaling through the leukemia inhibitory factor receptor. This 190kDa subunit couples with the 130kDa gp130 subunit to transduce intracellular signaling in neurons and oligodendrocytes that leads to expression of genes associated with neurosurvival. Moreover, activation of th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.08.008

    authors: Davis SM,Pennypacker KR

    更新日期:2018-03-01 00:00:00

  • Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches.

    abstract::The vascular endothelium not only is a single monolayer of cells between the vessel lumen and the intimal wall, but also plays an important role by controlling vascular function and structure mainly via the production of nitric oxide (NO). The so called "cardiovascular risk factors" are associated with endothelial dys...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.06.003

    authors: Tousoulis D,Simopoulou C,Papageorgiou N,Oikonomou E,Hatzis G,Siasos G,Tsiamis E,Stefanadis C

    更新日期:2014-12-01 00:00:00

  • GPCR interacting proteins (GIP).

    abstract::G protein-coupled receptors (GPCR) interact not only with heterotrimeric G proteins but also with accessory proteins called GPCR interacting proteins (GIP). These proteins have important functions. They are implicated in GPCR targeting to specific cellular compartments, in their assembling into large functional comple...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2004.06.004

    authors: Bockaert J,Fagni L,Dumuis A,Marin P

    更新日期:2004-09-01 00:00:00

  • Thyroid hormone and the brain: Mechanisms of action in development and role in protection and promotion of recovery after brain injury.

    abstract::Thyroid hormone (TH) is essential for normal brain development and may also promote recovery and neuronal regeneration after brain injury. TH acts predominantly through the nuclear receptors, TH receptor alpha (THRA) and beta (THRB). Additional factors that impact TH action in the brain include metabolism, activation ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.01.007

    authors: Liu YY,Brent GA

    更新日期:2018-06-01 00:00:00

  • The birth of artemisinin.

    abstract::As the first-line antimalarial drugs, artemisinins gained wide acceptance after the emergence of resistance to chloroquine in the 1950s. Artemisinin-based drugs have saved lives, especially in developing countries. The discovery of artemisinin was unique, timely, and fascinating, and the benefits of artemisinin were w...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107658

    authors: Ma N,Zhang Z,Liao F,Jiang T,Tu Y

    更新日期:2020-12-01 00:00:00

  • Ross River virus: molecular and cellular aspects of disease pathogenesis.

    abstract::Ross River virus (RRV) is a mosquito-borne alphavirus indigenous to Australia and the Western Pacific region and is responsible for several thousand cases of human RRV disease (RRVD) per annum. The disease primarily involves polyarthritis/arthralgia, with many patients also presenting with rash, myalgia, fever, and/or...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.03.006

    authors: Rulli NE,Suhrbier A,Hueston L,Heise MT,Tupanceska D,Zaid A,Wilmes A,Gilmore K,Lidbury BA,Mahalingam S

    更新日期:2005-09-01 00:00:00

  • HMGB1 and repair: focus on the heart.

    abstract::High-mobility group box 1 (HMGB1) is one of the most abundant proteins in eukaryotes and the best characterized damage-associated molecular pattern (DAMP). The biological activities of HMGB1 depend on its subcellular location, context and post-translational modifications. Inside the nucleus, HMGB1 is engaged in many D...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.12.005

    authors: Pellegrini L,Foglio E,Pontemezzo E,Germani A,Russo MA,Limana F

    更新日期:2019-04-01 00:00:00

  • The role of receptor structure in determining adenosine receptor activity.

    abstract::Adenosine produces a wide variety of physiological effects through the activation of cell surface adenosine receptors (ARs). ARs are members of the G-protein-coupled receptor family, and currently, four subtypes, the A1AR, A2AAR, A2BAR, and A3AR, are recognized. This review focuses on the role of receptor structure in...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(99)00051-0

    authors: Olah ME,Stiles GL

    更新日期:2000-02-01 00:00:00

  • Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases.

    abstract::Nitric oxide (NO) exerts a variety of biological actions under both physiological and pathological conditions. NO is synthesized by three distinct NO synthase (NOS) isoforms, including neuronal (nNOS), inducible (iNOS), and endothelial NOS (eNOS), all of which are expressed in the human cardiovascular system. The role...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.08.010

    authors: Tsutsui M,Shimokawa H,Otsuji Y,Yanagihara N

    更新日期:2010-12-01 00:00:00

  • Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis.

    abstract::RSV infection of the lower respiratory tract in infants is the leading cause of pediatric hospitalizations and second to malaria in causing infant deaths worldwide. RSV also causes substantial morbidity in immunocompromised and elderly populations. The only available therapeutic is a prophylactic drug called Palivizum...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107712

    authors: Elawar F,Oraby AK,Kieser Q,Jensen LD,Culp T,West FG,Marchant DJ

    更新日期:2020-10-27 00:00:00

  • Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.

    abstract::Glucose-6-phospate dehydrogenase (G6PD) deficiency is estimated to affect more than 400 million people world-wide. This X-linked genetic deficiency puts stress on red blood cells (RBC), which may be further augmented under certain pathophysiological conditions and drug treatments. These conditions can cause hemolytic ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107788

    authors: Ryan K,Tekwani BL

    更新日期:2020-12-14 00:00:00

  • Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.

    abstract::Cardiovascular diseases (CVDs) remain the leading cause of death in the developed countries. Taking into account the mounting evidence about the role of cytochrome P450 (CYP) enzymes in cardiovascular physiology, CYP polymorphisms can be considered one of the major determinants of individual susceptibility to CVDs. On...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.12.002

    authors: Zordoky BN,El-Kadi AO

    更新日期:2010-03-01 00:00:00

  • Clues to asthma pathogenesis from microarray expression studies.

    abstract::Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness (AHR), tissue remodeling, and airflow obstruction. The pathogenesis of asthma is only partly understood, and there is an urgent need for improved therapeutic strategies for this disease. Microarray technology has considerable promise ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.08.009

    authors: Rolph MS,Sisavanh M,Liu SM,Mackay CR

    更新日期:2006-01-01 00:00:00

  • Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity.

    abstract::Cytotoxic drug-induced nausea and vomiting are the side effects most feared by cancer patients. Emesis is an instinctive defense reaction caused by the somatoautonomic nerve reflex, which is integrated in the medulla oblongata. Emesis caused by cytotoxic drugs such as cisplatin is associated with an increase in the co...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(03)00057-3

    authors: Minami M,Endo T,Hirafuji M,Hamaue N,Liu Y,Hiroshige T,Nemoto M,Saito H,Yoshioka M

    更新日期:2003-08-01 00:00:00

  • Potassium channel activation: a potential therapeutic approach?

    abstract::The physiological role of K+ channel opening by endogenous substances (e.g., neurotransmitters and hormones) is a recognised inhibitory mechanism. Thus, the identification of novel synthetic molecules that 'directly' open K+ channels has led to a new direction in the pharmacology of ion channels. The existence of many...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(96)00003-4

    authors: Lawson K

    更新日期:1996-01-01 00:00:00

  • Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.

    abstract::Dipeptidyl peptidase 4 (DPP4, DPPIV, CD26, EC 3.4.14.5) was discovered more than four decades ago as a serine protease that cleaves off N-terminal dipeptides from peptide substrates. The development of potent DPP4 inhibitors during the past two decades has led to the identification of DPP4 as a target in the treatment...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.07.012

    authors: Matheeussen V,Jungraithmayr W,De Meester I

    更新日期:2012-12-01 00:00:00

  • Glutathione metabolism and its role in hepatotoxicity.

    abstract::Glutathione (GSH) fulfills several essential functions: Detoxification of free radicals and toxic oxygen radicals, thiol-disulfide exchange and storage and transfer of cysteine. GSH is present in all mammalian cells, but may be especially important for organs with intense exposure to exogenous toxins such as the liver...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90029-l

    authors: DeLeve LD,Kaplowitz N

    更新日期:1991-12-01 00:00:00

  • Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?

    abstract::Progress in methods of investigating endothelial function in humans has led to the demonstration that endothelial dysfunction is an early process involved in the pathophysiology of cardiovascular diseases, and represents a new independent therapeutic target that may help to improve patient health. The administration o...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.03.015

    authors: Bellien J,Joannides R,Richard V,Thuillez C

    更新日期:2011-07-01 00:00:00

  • The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.

    abstract::Thoracic aortic aneurysms (TAAs) are a potential life-threatening disease with limited pharmacological treatment options. Current treatment options are aimed at lowering aortic hemodynamic stress, predominantly with β-adrenoceptor blockers. Increasing evidence supports a role for the renin-angiotensin system (RAS) in ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.04.002

    authors: Moltzer E,Essers J,van Esch JH,Roos-Hesselink JW,Danser AH

    更新日期:2011-07-01 00:00:00